Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia

Leukemia Research

Volumn 33, Issue 2, 2009, Pages 212-217

  Yeh, Chen Hsiung ^a   Tseng, Richard ^a   Zhang, Zhong ^a   Cortes, Jorge ^b   O'Brien, Susan ^b   Giles, Francis ^c   Hannah, Alison ^d   Estrov, Zeev ^b   Keating, Michael ^b   Kantarjian, Hagop ^b   Albitar, Maher ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Kosan Biosciences ^*  (United States)

Author keywords

Chronic myeloid leukemia; Circulating heat shock protein; Imatinib resistance

Indexed keywords

HEAT SHOCK PROTEIN 70; IMATINIB;

ADULT; AGED; ARTICLE; BLAST CELL; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACCELERATED PHASE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PYRIMIDINES; YOUNG ADULT;

EID: 57049115429     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.07.012     Document Type: Article

References (46)

1. Georgopoulos C., and Welch W.J. Role of the major heat shock proteins as molecular chaperones. Annu Rev Cell Biol 9 (1993) 601-634
2. Bukau B., and Horwich A.L. The Hsp70 and Hsp60 chaperone machines. Cell 92 (1998) 351-366
3. Castelli C., Rivoltini L., Rini F., Elli F., Estori A., et al. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 53 (2004) 227-233
4. Lindquist S., and Craig E.A. The heat-shock proteins. Annu Rev Genet 22 (1988) 631-677
5. Welch W.J. Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev 72 (1992) 1063-1081
6. Benjamin I.J., and McMillan D.R. Stress (heat shock) proteins: molecular chaperones in cardiovascular biology and disease. Circ Res 83 (1998) 117-132
7. Nylandsted J., Gyrd-Hansen M., Danielewicz A., Fehrenbacher N., Lademann U., et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med 200 (2004) 425-435
8. Jaattela M., Wissing D., Kokholm K., Kallunki T., and Egeblad M. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J 17 (1998) 6124-6134
9. Ravagnan L., Gurbuxani S., Susin S.A., Maisse C., Daugas E., et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 3 (2001) 839-843
10. Gurbuxani S., Schmitt E., Cande C., Parcellier A., Hammann A., et al. Heat shock protein 70-binding inhibits the nuclear import of apoptosis inducing factor. Oncogene 22 (2003) 6669-6678
11. Park H.S., Cho S.G., Kim C.K., Hwang H.S., Noh K.T., et al. Heat shock protein Hsp72 is a negative regulator of apoptosis signal-regulating kinase 1. Mol Cell Biol 22 (2002) 7721-7730
12. Ciocca D.R., and Calderwood S.K. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10 (2005) 86-103
13. Clark P.R., and Menoret A. The inducible Hsp70 as a marker of tumor immunogenicity. Cell Stress Chaperones 6 (2001) 121-125
14. Torronteguy C., Frasson A., Zerwes F., Winnikov E., da Silva V.D., et al. Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors. Cell Stress Chaperones 11 (2006) 34-43
15. Ray S., Lu Y., Kaufmann S.H., Gustafson W.C., Karp J.E., et al. Genomic mechanisms of p210 BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. J Biol Chem 279 (2004) 35604-35615
16. Pocaly M., Lagarde V., Etienne G., Ribeil J.A., Claverol S., et al. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia 21 (2007) 93-101
17. Jaattela M. Over-expression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells. Int J Cancer 60 (1995) 689-693
18. Seo J.S., Park Y.M., Kim J.I., Shim E.H., Kim C.W., et al. T cell lymphoma in transgenic mice expressing the human Hsp70 gene. Biochem Biophys Res Commun 218 (1996) 582-587
19. Volloch V.Z., and Sherman M.Y. Oncogenic potential of Hsp72. Oncogene 18 (1999) 3648-3651
20. Ciocca D.R., Clark G.M., Tandon A.K., Fuqua S.A., Welch W.J., et al. Heat shock protein Hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 85 (1993) 570-574
21. Lazaris A.C., Chatzigianni E.B., Panoussopoulos D., Tzimas G.N., Davaris P.S., et al. Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified. Breast Cancer Res Treat 43 (1997) 43-51
22. Vargas-Roig L.M., Fanelli M.A., Lopez L.A., Gago F.E., Tello O., et al. Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect Prev 21 (1997) 441-451
23. Vargas-Roig L.M., Gago F.E., Tello O., Aznar J.C., and Ciocca D.R. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 79 (1998) 468-475
24. Nylandsted J., Rohde M., Brand K., Bastholm L., Elling F., et al. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci USA 97 (2000) 7871-7876
25. Nylandsted J., Wick W., Hirt U.A., Brand K., Rohde M., et al. Eradication of glioblastoma and breast and colon carcinoma xenografts by Hsp70 depletion. Cancer Res 62 (2002) 7139-7142
26. Calderwood S.K., Mambula S.S., and Gray Jr. P.J. Extracellular heat shock proteins in cell signaling and immunity. Ann N Y Acad Sci 1113 (2007) 28-39
27. Guo F., Sigua C., Bali P., George P., Fiskus W., et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 105 (2005) 1246-1255
28. Creagh E.M., Sheehan D., and Cotter T.G. Heat shock proteins-modulators of apoptosis in tumour cells. Leukemia 14 (2000) 1161-1173
29. Takayama S., Reed J.C., and Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 22 (2003) 9041-9047
30. Goldman J.M. Chronic myeloid leukemia-still a few questions. Exp Hematol 32 (2004) 2-10
31. Deininger M.W., Goldman J.M., and Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 96 (2000) 3343-3356
32. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., et al. The biology of chronic myeloid leukemia. N Engl J Med 341 (1999) 164-172
33. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia. Nature 243 (1973) 290-293
34. Kurzrock R., Gutterman J.U., and Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319 (1988) 990-998
35. Konopka J., Watanabe S., and Witte O. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37 (1984) 1035-1042
36. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
37. Hochhaus A., Kreil S., Corbin A.S., La Rosée P., Müller M.C., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190-2196
38. Daub H., Specht K., and Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 3 (2004) 1001-1010
39. Lu Y., Jamieson L., Brasier A.R., and Fields A.P. NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival. Oncogene 20 (2001) 4777-4792
40. Amarante-Mendes G.P., Naekyung K.C., Liu L., Huang Y., Perkins C.L., et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 91 (1998) 1700-1705
41. Multhoff G., Botzler C., and Wiesnet M. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer 61 (1995) 272-279
42. Gastpar R., Gehrmann M., Bausero M.A., Asea A., Gross C., et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res 65 (2005) 5238-5247
43. Gross C., Koelch W., DeMaio A., Arispe N., and Multhoff G. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J Biol Chem 278 (2003) 41173-41181
44. Asea A., Rehli M., Kabingu E., Boch J.A., Bare O., et al. Novel signal transduction pathway utilized by extracellular HSP70 Role of Toll-like receptor (TLR) 2 and TLR4. J Biol Chem 277 (2002) 15028-15034
45. Mambula S.S., and Calderwood S.K. Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol 177 (2006) 7849-7857
46. Calderwood S.K. Chaperones and slow death: a recipe for tumor immunotherapy. Trends Biotechnol 23 (2005) 57-59